Abcuro is a discovery stage startup, developing a new class of immune modulatory of bio-therapeutics for the treatment of autoimmunity and cancer.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]
Agenus plans to discovers and developes novel immuno-oncology targets using intensive use of bioinformatics to interrogate the transcriptome of human disease together with ex-vivo validation in diseased tissue to uncover new approaches to target key compartments of the immune system.
An Undisclosed anti-mouse KLRG1 antibody is in preclinical development, which neutralized the interaction of KLRG1 with its ligands. KLRG1 is a lymphocyte co-inhibitory receptor, expressed predominantly on effector memory CD8+ T cells and NK cells, whose ligands E- and N-cadherin are differentially expressed during epithelial-mesenchymal transition.
In animal studies in the 4T1 murine breast cancer model, anti-KLRG1 antibody as monotherapy reduced lung metastases compared to control antibody. Also, combination therapy anti-KLRG1 + anti-PD-1 produced synergistic benefit significantly greater than that of anti-PD-1 alone for tumor volume and survival with combination therapy.
In Nov 2016, Abcuro raised $2.25 Mn in seed funding through the issue of Equity.